Answers are grounded in this paper and cite their sources.
The mini-review synthesizes the blood-borne Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) human pathogens in its clinical significance through Vesicular H+-Adenosine Triphosphatase (V-ATPase) that lead to pericarditis-induced sudden deaths with acute myocarditis, blood clots, and etc. Early symptoms may arise through rapid acidification in the blood and may guide patient self-awareness and clinical practices. A Phase III clinical trial is reviewed on its phase IV implications, and potentials of experimental medicine in inhibiting V-ATPase protons for Coronavirus Disease 2019 (COVID-19) transmembrane treatment. The mini-review calls for animal tests on Bafilomycin A1 treatment on SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Yang Pachankis (2023) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: